Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics (Nasdaq: DNTH) granted equity inducement awards under Nasdaq Listing Rule 5635(c)(4) to three newly hired non-executive employees on June 1, 2026.
Dianthus Therapeutics (Nasdaq: DNTH) granted equity inducement awards under Nasdaq Listing Rule 5635(c)(4) to three newly hired non-executive employees on June 1, 2026.
The awards are non-qualified stock options for an aggregate 60,000 shares at an exercise price of $89.45, with a 10-year term and a four-year vesting schedule.
In the Jun 3 session, DNTH gained 4.17%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Market Context
This announcement details inducement grants of 60,000 non-qualified stock options to three new emplo...
Analysis
This announcement details inducement grants of 60,000 non-qualified stock options to three new employees, with a 10-year term and an exercise price of $89.45 per share. Vesting follows the company’s standard pattern of 25% after one year and monthly vesting over 36 months. The news continues a series of routine option awards alongside earlier board grants and prior inducement plans, while the company also maintains an effective $600,000,000 S-3 shelf for broader financing flexibility.
Key Figures
Current price:$89.45Inducement options:60,000 sharesOption term:10 years+5 more
Current price
$89.45
DNTH share price at time of context
Inducement options
60,000 shares
Aggregate non-qualified stock options granted to three new employees
Option term
10 years
Term of inducement stock options
Exercise price
$89.45 per share
Exercise price of inducement options
Initial vesting tranche
25%
Vests on first anniversary of vesting commencement date
Subsequent vesting period
36 months
Remaining options vest in equal monthly installments
Shelf capacity
$600,000,000
Amount registered under January 28, 2026 S-3 shelf
"The inducement grants were approved... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
non-qualified stock optionsfinancial
"The inducement grants consist of non-qualified stock options to purchase an aggregate of 60,000 shares..."
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
exercise pricefinancial
"non-qualified stock options... with a 10-year term and an exercise price of $89.45 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting commencement datetechnical
"The options vest as to 25% on the first anniversary of the vesting commencement date..."
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on June 1, 2026, to three newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants consist of non-qualified stock options to purchase an aggregate of 60,000 shares of the Company's common stock with a 10-year term and an exercise price of $89.45 per share. The options vest as to 25% on the first anniversary of the vesting commencement date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan, and the terms and conditions of a stock option agreement.
About Dianthus Therapeutics Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity inducement grants did Dianthus Therapeutics (DNTH) announce on June 2, 2026?
Dianthus Therapeutics announced non-qualified stock option inducement grants covering an aggregate 60,000 shares. According to Dianthus, these options were granted on June 1, 2026, to three newly hired non-executive employees as a material inducement to join the company.
What is the exercise price and term of the new DNTH inducement stock options?
The inducement stock options have an exercise price of $89.45 per share and a 10-year term. According to Dianthus, these options allow the three new non-executive employees to purchase common shares at this fixed price over the option term.
How do the Dianthus Therapeutics (DNTH) inducement options granted in June 2026 vest?
The inducement options vest 25% on the first anniversary of the vesting commencement date, then monthly over 36 months. According to Dianthus, this four-year schedule is subject to the Equity Inducement Plan and individual stock option agreements.
Why did Dianthus Therapeutics (DNTH) use Nasdaq Listing Rule 5635(c)(4) for these grants?
Dianthus used Nasdaq Listing Rule 5635(c)(4) to grant options as material inducements to employment. According to Dianthus, the independent Compensation Committee approved these non-qualified stock options specifically to attract and retain three newly hired non-executive employees.
How many employees received DNTH inducement stock options in June 2026 and at what level?
Three newly hired non-executive employees received the inducement stock options. According to Dianthus, these awards are intended as a material inducement to accept employment and are granted outside the standard shareholder-approved equity compensation plans.
